Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating F

WESTMINSTER, Colo., Dec. 12  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the presentation of new findings from its Phase 3 clinical trial of the investigational radiation sensitizer EFAPROXYN(TM) (efaproxiral) in patients with brain metastases.  Preliminary data from the Phase 3 study, called REACH, were first announced in April 2003. Charles Scott, Ph.D., CBS Squared, presented the findings in a poster presentation Saturday at the 28th Annual San Antonio Breast Cancer Symposium.

In abstract #4040, titled "Improved Survival, Quality of Life (QOL), and Quality-Adjusted Survival (QAS) in Breast Cancer Patients Treated with Efaproxiral (EFAPROXYN(TM)) and Whole Brain Radiation Therapy (WBRT) for Brain Metastases," Dr. Scott presented a QAS analysis of data from the Company's Phase 3 REACH study, which compared the survival benefit of brain metastases patients receiving EFAPROXYN with WBRT to those receiving WBRT alone.  Results of the analysis indicated that the addition of EFAPROXYN to WBRT led to a statistically significant increase in survival for EFAPROXYN-arm patients with brain metastases originating from breast cancer, which was accompanied by a statistically significant improvement in both QOL and QAS, a composite measure of quality and duration of survival.   Specifically, EFAPROXYN-arm patients with brain metastases originating from breast cancer experienced a slower overall decline in Spitzer Quality of Life Index (SQLI) scores over time (p